Mosier D E
Department of Immunology-IMM7, The Scripps Research Institute, La Jolla, CA 92037, USA.
Curr Opin Hematol. 1999 Jan;6(1):25-9. doi: 10.1097/00062752-199901000-00005.
The Epstein-Barr virus is a ubiquitous human herpesvirus that is associated with an increasing number of human malignancies. Among these are Epstein-Barr virus-associated lymphoproliferative diseases in immunocompromised patients, a spectrum of mainly B-cell diseases that range from polyclonal lymphoproliferative diseases, which resolve when immunosuppression is halted, to highly malignant lymphomas. Progress has identified Epstein-Barr virus gene products involved in B-cell transformation, variation in Epstein-Barr virus transforming genes, distinct target cell populations with differing regulation of Epstein-Barr virus expression, and selective recruitment of other supportive cell types as factors in the heterogeneity of lymphoproliferative diseases. New therapeutic approaches to treat lymphoproliferative diseases are also being developed. Finally, xenotransplantation poses new risks for the introduction of Epstein-Barr virus-like viruses and more aggressive lymphoproliferative diseases in heavily immunosuppressed patients.
爱泼斯坦-巴尔病毒是一种普遍存在的人类疱疹病毒，与越来越多的人类恶性肿瘤相关。其中包括免疫功能低下患者中与爱泼斯坦-巴尔病毒相关的淋巴增殖性疾病，这是一系列主要的B细胞疾病，范围从免疫抑制停止后可消退的多克隆淋巴增殖性疾病到高度恶性淋巴瘤。研究进展已确定了参与B细胞转化的爱泼斯坦-巴尔病毒基因产物、爱泼斯坦-巴尔病毒转化基因的变异、具有不同爱泼斯坦-巴尔病毒表达调控的不同靶细胞群体，以及其他支持性细胞类型的选择性募集，这些都是淋巴增殖性疾病异质性的因素。治疗淋巴增殖性疾病的新治疗方法也在不断开发。最后，异种移植给严重免疫抑制患者带来了引入爱泼斯坦-巴尔病毒样病毒和更具侵袭性的淋巴增殖性疾病的新风险。
